Reducing Vertigo in Meniere’s Disease with a CGRP Blocker

​Principal Investigator: Dr. Jeffrey Sharon

Disease: Meniere’s disease

Research Description: Meniere’s disease is a debilitating inner ear disease marked by attacks of vertigo, hearing loss, tinnitus and ear pressure affecting roughly 600,000 people in the US with no FDA approved treatments. For reasons not yet well understood, approximately half of patients with Meniere’s disease also have a history of migraines, suggesting a link between migraine and Meniere’s disease pathology. A brain chemical called CGRP causes inflammation and is released during a migraine attack. In addition, CGRP receptors are found in the inner ear, making it a potential target for Meniere’s disease therapies. This Phase IIA randomized, placebo-controlled clinical trial is testing Ubrogepant, a CGRP receptor-blocking drug approved for migraines, to reduce vertigo and improve Meniere’s disease patients’ lives.

Funding Partners: Becky and Lester Knight

Initial CWR Funding Role: Primary